»é¼ÁÂå¼Õ°Û¾ï¤ËÂФ¹¤ë·ì±Õ¾ô²½ÎÅË¡
¤³¤ì¤Ï¥¦¥Á¤Ç¹Ô¤Ã¤Æ¤¤¤ë¤ï¤±¤Ç¤Ï¤Ê¤¯¡¢¶µ²Ê½ñ¤ÇÆÉ¤ó¤ÇÃΤäƤ¤¤ë¡¢¤È¤¤¤¦ÄøÅ٤Ǥ¹¡£
¤¿¤À¡¢°ÊÁ°¡¢Y¸©¤ÎYɱ¡¤Ç¼ÂºÝ¤Ë¹Ô¤Ã¤Æ¤¤¤ëÊý¤¬µï¤é¤ì¤¿¤Î¤Ç¡¢ÎÅË¡¤½¤Î¤â¤Î¤ÏÁ¯ÌÀ¤Ê¥¤¥á¡¼¥¸¤Ç¤¹¡£
·ì±Õ¾ô²½ÎÅË¡¤ÎŬ±þ¤È¤Ê¤ë»é¼ÁÂå¼Õ°Û¾ï¤È¤·¤Æ¤Ï¡¢²È²À¹â»é·ì¾É¤ÈÊĺÉÀư̮¹Å²½¾É(ASO:ArteripSclerosis Obliterans)¤¬µó¤²¤é¤ì¤Þ¤¹¡£
²È²À¹â»é·ì¾É¤Ï¡¢·ìÞùÃæ¤ÎÄãÈæ½Å¥ê¥ÝÃÁÇò¡ÊLDL¡§Low Density Lipoprotein)¤ò°Û²½¤¹¤ëLDL¼õÍÆÂξ㳲¤Î¤¿¤á¡¢LDL¤¬ÃßÀÑ¡¦ÊÑÀ¤µ¤ì¤Æ¡¢²«¿§¼ð¤ä·ì´ÉÉÂÊѤòÀ¸¤¸¤ë¾ïÀ÷¿§ÂÎÍ¥À°äÅÁ¼À´µ¤Ç¤¹¡£
ÃßÀѤ·¤¿LDL¤ò½üµî¤¹¤ë¤¿¤á¤ËDFPP¤äLDLµÛÃåÎÅË¡(LDL-A)¤¬¹Ô¤ï¤ì¤Þ¤¹¡£
Á°¼Ô¤Ï·ìÞùʬ²èËì¤òÍѤ¤¤ÆÊ¬»ÒÎ̤ΰ㤤¤Ë¤è¤êLDL¤ò½üµî¡¢¸å¼Ô¤ÏµÛÃå´ï¤Ë¤ÆLDL¤òµÛÃ夹¤ë»ö¤Ç½üµî¤·¤Þ¤¹¡£
¤³¤ÎLDL-A¤Ë¤Ä¤¤¤Æ¤Ï¼ÂºÝ¤Ë¸«³Ø¤µ¤»¤Æ¤¤¤¿¤À¤¤Þ¤·¤¿¡£
ÀìÍѤÎÁõÃÖ¤òÍѤ¤¤Æ¡¢LDLµÛÃå´ï¤ò£²¤Ä¡¢ÊÂÎó¤ËÁõÃ夷¤Æ¹Ô¤Ã¤Æ¤¤¤Þ¤·¤¿¡£
ºÇ½é¤ËÊÒÊý¤ÎµÛÃå´ï¤Î¤ß¤ò»È¤Ã¤Æ·ì±Õ¤ò´Ôή¤µ¤»¡¢·ì±Õ½èÍýÎ̤¬600mlÄøÅ٤ˤʤë¤È¡¢¤â¤¦ÊÒÊý¤ò»È¤Ã¤Æ·ì±Õ¤ò´Ôή¤µ¤»¤Æ½üµî¤·¤Æ¤¤¤Þ¤·¤¿¡£
¤½¤ÎºÝ¡¢ºÇ½é¤ÎµÛÃå´ï¤ÎÊý¤Ë¤Ï·ì±Õ¤¬Î®¤ì¤Ê¤¤¤è¤¦¤Ë¡¢ÁõÃÖ¤ÎÅż§ÊۤDzóÏ©¤ò¼×ÃǤ·¡¢¥á¡¼¥«¿ä¾©¤Î¥é¥¯¥Æ¥Ã¥¯G¤ò»È¤Ã¤ÆÀö¤¤Î®¤·¤Æ¤¤¤Þ¤·¤¿¡£
¤½¤·¤Æ·ì±Õ½èÍýÎ̤¬600mlÄøÅ٤ˤʤë¤È¡¢ºÇ½é¤ÎµÛÃå´ï¤Ë·ì±Õ¤òή¤·¡¢2ËÜÌܤεÛÃå´ï¤ò¥é¥¯¥Æ¥Ã¥¯G¤ÇÀö¤¤Î®¤¹¤È¤¤¤¦É÷¤Ë£²ËܤεÛÃå´ï¤ò¸ò¸ß¤Ë»ÈÍѤ·¤Æ½üµî¤¹¤ë¡¢¤È¤¤¤¦ÊýË¡¤Ç¤·¤¿¡£
¥é¥¯¥Æ¥Ã¥¯G¤Ç¤Ï¤Ê¤¯¤ÆÀ¸¿©¤Ç¤âÎɤ¤¤ß¤¿¤¤¤Ç¤¹¡£
·ì±ÕÆ©ÀϤȤϰã¤Ã¤Æ½µ1²óÄøÅ٤Ǥ·¤¿¡£
¤¿¤À¡¢¿©»öÎÅË¡¤âɬÍפÊÍͤǤ¹¤Í¡£¿§¡¹¤ÈµºÜ¤¬Â¿¤«¤Ã¤¿¤Ç¤¹¡£
°ì¸«¤¹¤ë¤È²óÏ©¤ÏÈó¾ï¤ËÊ£»¨¤Ç¡¢²óÏ©¤Îή¤ì¤ò¥á¥âÄ¥¤Ë½ñ¤¼Ì¤¹¤Î¤Ë¤Á¤ç¤Ã¤È¶ìÏ«¤·¤Þ¤·¤¿¡£
ÊĺÉÀư̮¹Å²½¾É¤Ë¤Ä¤¤¤Æ¤Ï¡¢¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë·ì¾É¤¬´í¸±°ø»Ò¤È¤·¤Æ¹Í¤¨¤é¤ì¤Æ¤¤¤ë¤Î¤Ç¡¢LDL½üµîÌÜŪ¤ÇDFPP¤äLDL-A¤ò¹Ô¤¤¤Þ¤¹¡£
¤½¤ì°Ê³°¤Ë¤â¡¢·ì±Õ¡¦·ìÞùÇ´ÅÙ¡¦ÀÖ·ìµåÊÑÀ·ÁÂ֤βþÁ±¥Ö¥é¥¸¥¥Ë¥ó¡¦°ì»À²½ÃºÁÇ¡ÊNO)¤Ê¤É¤Î·ì´É³ÈÄ¥°ø»Ò¤ÎÁý²Ã¡¢¥Õ¥£¥Ö¥ê¥Î¡¼¥²¥ó¤Ê¤É¤Î¶Å¸Ç°ø»Ò¤ÎÄã²¼¡¢ºÙÉôÀÜÃå°ø»Ò¤ÎÄã²¼¡¢·ì¾®ÈijèÀ²½¤ÎÍÞÀ©¡¢LDL¤Î°×»À²½À¤ÎÍÞÀ©¤Ê¤É¤¬¹Í¤¨¤é¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¹¡£

¤Ë¤Û¤ó¥Ö¥í¥°Â¼
¤¿¤À¡¢°ÊÁ°¡¢Y¸©¤ÎYɱ¡¤Ç¼ÂºÝ¤Ë¹Ô¤Ã¤Æ¤¤¤ëÊý¤¬µï¤é¤ì¤¿¤Î¤Ç¡¢ÎÅË¡¤½¤Î¤â¤Î¤ÏÁ¯ÌÀ¤Ê¥¤¥á¡¼¥¸¤Ç¤¹¡£
·ì±Õ¾ô²½ÎÅË¡¤ÎŬ±þ¤È¤Ê¤ë»é¼ÁÂå¼Õ°Û¾ï¤È¤·¤Æ¤Ï¡¢²È²À¹â»é·ì¾É¤ÈÊĺÉÀư̮¹Å²½¾É(ASO:ArteripSclerosis Obliterans)¤¬µó¤²¤é¤ì¤Þ¤¹¡£
²È²À¹â»é·ì¾É¤Ï¡¢·ìÞùÃæ¤ÎÄãÈæ½Å¥ê¥ÝÃÁÇò¡ÊLDL¡§Low Density Lipoprotein)¤ò°Û²½¤¹¤ëLDL¼õÍÆÂξ㳲¤Î¤¿¤á¡¢LDL¤¬ÃßÀÑ¡¦ÊÑÀ¤µ¤ì¤Æ¡¢²«¿§¼ð¤ä·ì´ÉÉÂÊѤòÀ¸¤¸¤ë¾ïÀ÷¿§ÂÎÍ¥À°äÅÁ¼À´µ¤Ç¤¹¡£
ÃßÀѤ·¤¿LDL¤ò½üµî¤¹¤ë¤¿¤á¤ËDFPP¤äLDLµÛÃåÎÅË¡(LDL-A)¤¬¹Ô¤ï¤ì¤Þ¤¹¡£
Á°¼Ô¤Ï·ìÞùʬ²èËì¤òÍѤ¤¤ÆÊ¬»ÒÎ̤ΰ㤤¤Ë¤è¤êLDL¤ò½üµî¡¢¸å¼Ô¤ÏµÛÃå´ï¤Ë¤ÆLDL¤òµÛÃ夹¤ë»ö¤Ç½üµî¤·¤Þ¤¹¡£
¤³¤ÎLDL-A¤Ë¤Ä¤¤¤Æ¤Ï¼ÂºÝ¤Ë¸«³Ø¤µ¤»¤Æ¤¤¤¿¤À¤¤Þ¤·¤¿¡£
ÀìÍѤÎÁõÃÖ¤òÍѤ¤¤Æ¡¢LDLµÛÃå´ï¤ò£²¤Ä¡¢ÊÂÎó¤ËÁõÃ夷¤Æ¹Ô¤Ã¤Æ¤¤¤Þ¤·¤¿¡£
ºÇ½é¤ËÊÒÊý¤ÎµÛÃå´ï¤Î¤ß¤ò»È¤Ã¤Æ·ì±Õ¤ò´Ôή¤µ¤»¡¢·ì±Õ½èÍýÎ̤¬600mlÄøÅ٤ˤʤë¤È¡¢¤â¤¦ÊÒÊý¤ò»È¤Ã¤Æ·ì±Õ¤ò´Ôή¤µ¤»¤Æ½üµî¤·¤Æ¤¤¤Þ¤·¤¿¡£
¤½¤ÎºÝ¡¢ºÇ½é¤ÎµÛÃå´ï¤ÎÊý¤Ë¤Ï·ì±Õ¤¬Î®¤ì¤Ê¤¤¤è¤¦¤Ë¡¢ÁõÃÖ¤ÎÅż§ÊۤDzóÏ©¤ò¼×ÃǤ·¡¢¥á¡¼¥«¿ä¾©¤Î¥é¥¯¥Æ¥Ã¥¯G¤ò»È¤Ã¤ÆÀö¤¤Î®¤·¤Æ¤¤¤Þ¤·¤¿¡£
¤½¤·¤Æ·ì±Õ½èÍýÎ̤¬600mlÄøÅ٤ˤʤë¤È¡¢ºÇ½é¤ÎµÛÃå´ï¤Ë·ì±Õ¤òή¤·¡¢2ËÜÌܤεÛÃå´ï¤ò¥é¥¯¥Æ¥Ã¥¯G¤ÇÀö¤¤Î®¤¹¤È¤¤¤¦É÷¤Ë£²ËܤεÛÃå´ï¤ò¸ò¸ß¤Ë»ÈÍѤ·¤Æ½üµî¤¹¤ë¡¢¤È¤¤¤¦ÊýË¡¤Ç¤·¤¿¡£
¥é¥¯¥Æ¥Ã¥¯G¤Ç¤Ï¤Ê¤¯¤ÆÀ¸¿©¤Ç¤âÎɤ¤¤ß¤¿¤¤¤Ç¤¹¡£
·ì±ÕÆ©ÀϤȤϰã¤Ã¤Æ½µ1²óÄøÅ٤Ǥ·¤¿¡£
¤¿¤À¡¢¿©»öÎÅË¡¤âɬÍפÊÍͤǤ¹¤Í¡£¿§¡¹¤ÈµºÜ¤¬Â¿¤«¤Ã¤¿¤Ç¤¹¡£
°ì¸«¤¹¤ë¤È²óÏ©¤ÏÈó¾ï¤ËÊ£»¨¤Ç¡¢²óÏ©¤Îή¤ì¤ò¥á¥âÄ¥¤Ë½ñ¤¼Ì¤¹¤Î¤Ë¤Á¤ç¤Ã¤È¶ìÏ«¤·¤Þ¤·¤¿¡£
ÊĺÉÀư̮¹Å²½¾É¤Ë¤Ä¤¤¤Æ¤Ï¡¢¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë·ì¾É¤¬´í¸±°ø»Ò¤È¤·¤Æ¹Í¤¨¤é¤ì¤Æ¤¤¤ë¤Î¤Ç¡¢LDL½üµîÌÜŪ¤ÇDFPP¤äLDL-A¤ò¹Ô¤¤¤Þ¤¹¡£
¤½¤ì°Ê³°¤Ë¤â¡¢·ì±Õ¡¦·ìÞùÇ´ÅÙ¡¦ÀÖ·ìµåÊÑÀ·ÁÂ֤βþÁ±¥Ö¥é¥¸¥¥Ë¥ó¡¦°ì»À²½ÃºÁÇ¡ÊNO)¤Ê¤É¤Î·ì´É³ÈÄ¥°ø»Ò¤ÎÁý²Ã¡¢¥Õ¥£¥Ö¥ê¥Î¡¼¥²¥ó¤Ê¤É¤Î¶Å¸Ç°ø»Ò¤ÎÄã²¼¡¢ºÙÉôÀÜÃå°ø»Ò¤ÎÄã²¼¡¢·ì¾®ÈijèÀ²½¤ÎÍÞÀ©¡¢LDL¤Î°×»À²½À¤ÎÍÞÀ©¤Ê¤É¤¬¹Í¤¨¤é¤ì¤Æ¤¤¤ë¤è¤¦¤Ç¤¹¡£
»²¹Í¡¦°úÍÑʸ¸¥
Æ©ÀÏ´µ¼Ô¤ÎÉÂÂ֤ؤΥ¢¥×¥í¡¼¥Á¡§ÊÔ½¸¡§¿¼Àî²í»Ë¡¢½ÐÈǼҡ§¶â˧Ʋ
¤Ë¤Û¤ó¥Ö¥í¥°Â¼



